Fifteen years of coronary intravascular ultrasound in percutaneous coronary intervention in Portugal. / Quinze anos de ecografia intravascular coronária em intervenção coronária percutânea em Portugal.

INTRODUCTION: Coronary intravascular ultrasound (IVUS) is increasingly important in catheterization laboratories due to its positive prognostic impact. This study aims to characterize the use of IVUS in percutaneous coronary intervention (PCI) in Portugal. METHODS: A retrospective observational study was performed based on the Portuguese Registry on Interventional Cardiology of the Portuguese Society of Cardiology. The clinical and angiographic profiles of patients who underwent PCI between 2002 and 2016, the percentage of IVUS use, and the coronary arteries assessed were characterized. RESULTS: A total of 118 706 PCIs were included, in which IVUS was used in 2266 (1.9%). Over time, use of IVUS changed from none in 2002 to generally increasing use from 2003 (0.1%) to 2016 (2.4%). The age of patients in whom coronary IVUS was used was similar to that of patients in whom IVUS was not used, but in the former group there were fewer male patients, and a higher prevalence of cardiovascular risk factors (hypertension, hypercholesterolemia and diabetes), previous myocardial infarction, previous PCI, multivessel coronary disease, C-type or bifurcated coronary lesions, and in-stent restenosis. IVUS was used in 54.8% of elective PCIs and in 19.15% of PCIs of the left main coronary artery. CONCLUSION: Coronary IVUS has been increasingly used in Portugal since 2003. It is used preferentially in elective PCIs, and in patients with higher cardiovascular risk, with more complex coronary lesions and lesions of the left main coronary artery.

Safety evaluation of the use of femural percutaneous closure systems with simultaneous use of abciximab.

INTRODUCTION: The growing use of abciximab during coronary angioplasty, with 12 hours of intravenous perfusion, prolongs hospital stay and increases the risk of hemorrhage after sheath removal at the puncture site. Femoral percutaneous closure devices can reduce immobilization time, but their safety in the presence of abciximab in respect to hemorrhage has not been clearly determined. OBJECTIVES: To evaluate the safety and efficacy of the Perclose system in patients undergoing angioplasty with abciximab. POPULATION AND METHODS: The Perclose system was used in 79 patients undergoing angioplasty, with abciximab in 31 patients (58.6 +/- 12.2 years, 90% male, p = NS)--Group 1, and 48 pts without abciximab (61.8 +/- 10.9 years, 79% male, p = NS)--Group 2. We compared heparin dose, sheath diameters, primary success rate, coronary care unit admissions and minor and major complications. One patient was previously anticoagulated with warfarin and all the others were on oral antiplatelet therapy before and after angioplasty. RESULTS: Primary success with the use of the Perclose system was 78%. We found no significant statistical differences between groups in respect to the presence of diabetes, sheath diameter or referral for intervention. Heparin dosage was slightly higher in group 2 (p = 0.09) and ACT was also higher in group 2 (p = 0.01). More patients in group 1 had delayed ambulation (p = 0.04) due to abciximab perfusion. In 7 patients in group 1 and 9 in group 2, additional manual/mechanical compression was needed for moderate bleeding in the first hours (p = NS). One rupture of the femoral artery with need for surgical repair (primary failure) and another delayed rupture (48 hours) occurred in group 1 (both with an associated infection), and 1 pseudoaneurysm in a patient from group 2, without abciximab but taking warfarin (p = NS). None of the variables analyzed determined the occurrence of complications. Only oral anticoagulation determined the occurrence of major complications. CONCLUSIONS: User of the Perclose system for percutaneous closure of the femoral artery in patients undergoing coronary angioplasty with simultaneous use of abciximab was not associated with greater morbidity than in patients without glycoprotein IIb/IIIa receptor antagonists.

Identification of pulmonary vein foci by non-contact mapping in patients with paroxysmal atrial fibrillation.

AIMS: Ectopies from the pulmonary veins may cause paroxysmal atrial fibrillation and their discrete ablation may be curative. In the absence of focal activity during the procedure, identification of target sites with conventional techniques is difficult. We investigated the feasibility of non-contact mapping (EnSite) for identification and successful ablation of pulmonary vein foci in such cases. METHODS AND RESULTS: We studied 7 patients with idiopathic paroxysmal atrial fibrillation referred for percutaneous ablation and not presenting spontaneous or inducible atrial premature beats during the procedure. An EnSite balloon catheter and an ablation catheter (NaviStar) were placed inside the left atrium. The ablation catheter was also used for electroanatomic mapping (CARTO) of specific sites. Multiphasic pulmonary vein potentials were detected on virtual electrograms and tagged on the non-contact map and confirmed with conventional mapping. The procedural endpoint was elimination or dissociation of the multiphasic potential. Non-contact mapping identified 13 foci of multiphasic potentials in the seven patients (5 foci were initially identified by EnSite), and discrete ablation suppressed 9 of them (69%). Six months later, 4 of the 5 patients in whom all foci were suppressed remain asymptomatic, in sinus rhythm, under no medication. CONCLUSION: In patients with paroxysmal atrial fibrillation and no ectopic activity during electrophysiological study virtual electrograms may complement conventional techniques in detecting hidden pulmonary vein foci and may be used to evaluate ablation efficacy.

Electronanatomical mapping and ablation of atrial tachycardias with the CARTO system.

UNLABELLED: Variable success rates in the ablation of atrial tachycardias using conventional electrophysiology have been achieved. There is no precise relation between P wave morphology in surface ECG and atrial electrophysiology, and this fact makes it more difficult to locate ectopic atrial foci. The CARTO system creates atrial activation maps that relate an anatomical location to an electrical potential. The aim of this study was to evaluate the efficacy of CARTO guided radiofrequency (RF) ablation of atrial foci. The population consisted of 10 consecutive patients with atrial tachycardia resistant to more than 2 drugs, 7 female, mean age 45 +/- 12 years. CARTO activation maps were constructed based on atrial tachycardia or premature beats. Radiofrequency energy was applied to the earliest activation zone. Immediate success was defined as suppression of ectopic atrial activity. Ectopic foci were located on the ostium of the coronary sinus (3 patients), crista terminalis (1 patient), right atrial appendage (1 patient), interatrial septum (1 patient) and in the pulmonary veins (4 patients). The activation maps contained 85 +/- 35 points. The number of RF applications ranged from 1 to 11 (mean 4). Immediate and 6 month success rate was 90%. We were not able to treat one patient with a focus in the right atrial appendage. No attempt was made to limit procedure or fluoroscopy time in our study. Nonetheless all procedures lasted less than 150 min, and fluoroscopy times were less than 30 minutes. CONCLUSIONS: The CARTO system precisely located ectopic atrial foci, allowing a high success rate in the ablation of focal atrial tachycardias.